Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 333

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 333
---
 a VWAP Purchase, and on the applicable Additional VWAP
Purchase Date, with respect to an Additional VWAP Purchase, the number of shares that may actually be sold by us to the Selling Shareholder
under the Purchase Agreement may be fewer than the number of shares being offered by this prospectus. The fourth column assumes the sale
of all of the shares offered by the Selling Shareholder pursuant to this prospectus.

We may amend or supplement
this prospectus from time to time in the future to update or change the Selling Shareholder list and the securities that may be resold.

Please see the section titled
“Plan of Distribution” for further information regarding the Selling Shareholder’s method of distributing these
securities.

| Name of Selling Shareholder     |     | Number of Ordinary 
 Shares Owned Prior 
 to                 
 Offering (1)       |     | Maximum Number of  
 Ordinary Shares to 
 be Sold            
 Pursuant to this   
 Prospectus         |                 |     | Number of          
 Ordinary           
 Shares Owned After 
 Offering (2)       |     | Percentage   
 of           
 Ordinary     
 Shares       
 Owned        
 after the    
 Offering (3) |
| C/M Capital Master Fund, LP (4) |     | --                 |     |                    | 358,750,000,000 |     | --                 |     | --           |

__________________

| (1) | In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially                             
 owned prior to the offering all of the shares that the Selling Shareholder may be required to purchase under the Purchase Agreement, because 
 the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreement, the satisfaction   
 of which are entirely outside of the Selling Shareholder’s control, including the registration statement that includes this prospectus       
 becoming and remaining effective. Furthermore, the Fixed Purchases, VWAP Purchase, or Additional VWAP Purchase, as applicable, of Depositary 
 Shares is subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreement. Also, the Purchase Agreement        
 prohibits us from issuing and selling any of our Depositary Shares to the Selling Shareholder to the extent such shares, when aggregated     
 with all other securities then beneficially owned by the Selling Shareholder, would cause the Selling Shareholder beneficial ownership       
 of our Ordinary Shares to exceed the Beneficial Ownership Limitation.                                                                        |

| 166 |

| (2) | Assumes that all Ordinary Shares being